Guilin Sanjin Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Guilin Sanjin Pharmaceutical has been growing earnings at an average annual rate of 2.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.1% per year. Guilin Sanjin Pharmaceutical's return on equity is 13.5%, and it has net margins of 19.3%.
Key information
2.4%
Earnings growth rate
2.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.1% |
| Return on equity | 13.5% |
| Net Margin | 19.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Guilin Sanjin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,115 | 408 | 921 | 168 |
| 30 Jun 24 | 2,046 | 343 | 926 | 173 |
| 31 Mar 24 | 1,938 | 352 | 887 | 118 |
| 31 Dec 23 | 2,172 | 421 | 921 | 158 |
| 30 Sep 23 | 2,153 | 402 | 912 | 195 |
| 30 Jun 23 | 2,158 | 406 | 902 | 203 |
| 31 Mar 23 | 2,159 | 379 | 897 | 220 |
| 01 Jan 23 | 1,960 | 330 | 817 | 217 |
| 30 Sep 22 | 1,925 | 375 | 822 | 159 |
| 30 Jun 22 | 1,857 | 399 | 775 | 178 |
| 31 Mar 22 | 1,829 | 366 | 765 | 209 |
| 01 Jan 22 | 1,741 | 344 | 723 | 202 |
| 30 Sep 21 | 1,724 | 265 | 721 | 208 |
| 30 Jun 21 | 1,694 | 283 | 670 | 185 |
| 31 Mar 21 | 1,667 | 298 | 651 | 158 |
| 31 Dec 20 | 1,566 | 277 | 626 | 148 |
| 30 Sep 20 | 1,611 | 367 | 592 | 153 |
| 30 Jun 20 | 1,602 | 359 | 611 | 123 |
| 31 Mar 20 | 1,592 | 381 | 570 | 133 |
| 31 Dec 19 | 1,640 | 392 | 628 | 100 |
| 30 Sep 19 | 1,600 | 377 | 601 | 71 |
| 30 Jun 19 | 1,619 | 418 | 565 | 74 |
| 31 Mar 19 | 1,617 | 418 | 589 | 69 |
| 31 Dec 18 | 1,585 | 413 | 579 | 61 |
| 30 Sep 18 | 1,649 | 483 | 602 | 65 |
| 30 Jun 18 | 1,643 | 482 | 599 | 84 |
| 31 Mar 18 | 1,626 | 472 | 602 | 66 |
| 31 Dec 17 | 1,616 | 464 | 610 | 55 |
| 30 Sep 17 | 1,600 | 426 | 617 | 38 |
| 30 Jun 17 | 1,582 | 418 | 647 | 0 |
| 31 Mar 17 | 1,559 | 398 | 648 | 0 |
| 31 Dec 16 | 1,525 | 394 | 632 | 0 |
| 30 Sep 16 | 1,495 | 406 | 611 | 0 |
| 30 Jun 16 | 1,448 | 384 | 593 | 0 |
| 31 Mar 16 | 1,470 | 397 | 607 | 0 |
| 31 Dec 15 | 1,391 | 377 | 577 | 0 |
| 30 Sep 15 | 1,408 | 407 | 509 | 0 |
| 30 Jun 15 | 1,449 | 423 | 538 | 0 |
| 31 Mar 15 | 1,398 | 424 | 500 | 0 |
| 31 Dec 14 | 1,466 | 445 | 532 | 0 |
| 30 Sep 14 | 1,423 | 434 | 556 | 0 |
| 30 Jun 14 | 1,458 | 449 | 558 | 0 |
| 31 Mar 14 | 1,429 | 422 | 536 | 0 |
| 31 Dec 13 | 1,469 | 422 | 568 | 0 |
Quality Earnings: 002275 has a large one-off gain of CN¥84.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 002275's current net profit margins (19.3%) are higher than last year (18.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002275's earnings have grown by 2.4% per year over the past 5 years.
Accelerating Growth: 002275's earnings growth over the past year (1.6%) is below its 5-year average (2.4% per year).
Earnings vs Industry: 002275 earnings growth over the past year (1.6%) exceeded the Pharmaceuticals industry -1.2%.
Return on Equity
High ROE: 002275's Return on Equity (13.5%) is considered low.